Cite

HARVARD Citation

    Fehmi, J. et al. (2022). IgG1 pan-neurofascin antibodies define a severe and frequently fatal GBS-like neuropathy which responds to rituximab. Journal of neurology, neurosurgery and psychiatry. 93 (6), p. A1. [Online]. 
  
Back to record